Here, we report the case of a patient with advanced lung adenocarcinoma with negative driver genes, who benefited from treatment with anti-programmed cell death-1 (anti-PD-1) therapy combined with a low dose of apatinib. From February 2020, the patient was treated with camrelizumab combined with pemetrexed disodium. The treatment regimen was adjusted to camrelizumab combined with a low dose of apatinib every 3 weeks because the patient could not tolerate the side effects of the previous chemotherapy, and camrelizumab led to reactive cutaneous capillary endothelial proliferation (RCCEP). After six cycles of camrelizumab plus a low dose of apatinib, the curative effect achieved was complete response (CR), with milder symptoms of RCCEP than before. Until the follow-up time of March 2021, the efficacy evaluation reached CR and the symptoms of RCCEP disappeared. This case report provides a theoretical basis for camrelizumab combined with a low dose of apatinib for the treatment ofcarcinoma patients with advanced lung adenocarcinoma with negative driver genes.
Keywords: Advanced lung adenocarcinoma; apatinib; camrelizumab; immune checkpoint inhibitors; reactive cutaneous capillary endothelial proliferation.